Your browser doesn't support javascript.
loading
Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab.
Casey, R T; Giger, O; Seetho, I; Marker, A; Pitfield, D; Boyle, L H; Gurnell, M; Shaw, A; Tischkowitz, M; Maher, E R; Chatterjee, V K; Janowitz, T; Mells, G; Corrie, P; Challis, B G.
Afiliación
  • Casey RT; Department of Endocrinology and Diabetes, Cambridge University NHS Foundation Trust, Cambridge, UK; Department of Medical Genetics, Cambridge University, Cambridge, UK. Electronic address: rc674@medschl.cam.ac.uk.
  • Giger O; Department of Histopathology, Cambridge University NHS Foundation Trust, Cambridge, UK.
  • Seetho I; Department of Endocrinology and Diabetes, Cambridge University NHS Foundation Trust, Cambridge, UK.
  • Marker A; Department of Histopathology, Cambridge University NHS Foundation Trust, Cambridge, UK.
  • Pitfield D; Department of Endocrinology and Diabetes, Cambridge University NHS Foundation Trust, Cambridge, UK.
  • Boyle LH; Department of Pathology, University of Cambridge, Cambridge, UK.
  • Gurnell M; Department of Endocrinology and Diabetes, Cambridge University NHS Foundation Trust, Cambridge, UK.
  • Shaw A; Department of Radiology, Cambridge University NHS Foundation Trust, Cambridge, UK.
  • Tischkowitz M; Department of Medical Genetics, Cambridge University, Cambridge, UK.
  • Maher ER; Department of Medical Genetics, Cambridge University, Cambridge, UK.
  • Chatterjee VK; Department of Endocrinology and Diabetes, Cambridge University NHS Foundation Trust, Cambridge, UK.
  • Janowitz T; Department of Medical Oncology, Cambridge University NHS Foundation Trust, Cambridge, UK.
  • Mells G; Department of Hepatology, Cambridge University NHS Foundation Trust, Cambridge, UK.
  • Corrie P; Department of Medical Oncology, Cambridge University NHS Foundation Trust, Cambridge, UK.
  • Challis BG; Department of Endocrinology and Diabetes, Cambridge University NHS Foundation Trust, Cambridge, UK; IMED Biotech Unit, Clinical Discovery Unit, AstraZeneca, Cambridge, UK. Electronic address: bc340@medschl.cam.ac.uk.
Semin Oncol ; 45(3): 151-155, 2018 06.
Article en En | MEDLINE | ID: mdl-30262398
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndromes Neoplásicos Hereditarios / Neoplasias Encefálicas / Hidrocortisona / Neoplasias Colorrectales / Neoplasias de la Corteza Suprarrenal / Carcinoma Corticosuprarrenal / Anticuerpos Monoclonales Humanizados Tipo de estudio: Prognostic_studies Límite: Female / Humans / Middle aged Idioma: En Revista: Semin Oncol Año: 2018 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndromes Neoplásicos Hereditarios / Neoplasias Encefálicas / Hidrocortisona / Neoplasias Colorrectales / Neoplasias de la Corteza Suprarrenal / Carcinoma Corticosuprarrenal / Anticuerpos Monoclonales Humanizados Tipo de estudio: Prognostic_studies Límite: Female / Humans / Middle aged Idioma: En Revista: Semin Oncol Año: 2018 Tipo del documento: Article Pais de publicación: Estados Unidos